
Andreas Willerslev-Olsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2244842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. Dermatology, 2021, 237, 283-290.	0.9	8
2	MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells. Dermatology, 2021, 237, 277-282.	0.9	8
3	JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). Cancers, 2021, 13, 280.	1.7	17
4	Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 2449-2458.	0.3	15
5	Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis. Dermatology, 2020, 236, 123-132.	0.9	3
6	Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma. Frontiers in Cell and Developmental Biology, 2020, 8, 851.	1.8	28
7	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 ⁺ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. Oncolmmunology, 2020, 9, 1751561.	2.1	24
8	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. Cancers, 2020, 12, 1229.	1.7	28
9	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome. Blood Cancer Journal, 2020, 10, 57.	2.8	24
10	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood, 2019, 134, 1072-1083.	0.6	94
11	Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 ⁺ T cells in cutaneous T-cell lymphoma. Oncolmmunology, 2019, 8, e1641387.	2.1	32
12	Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome. Oncotarget, 2019, 10, 4894-4906.	0.8	3
13	Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL. Blood, 2019, 134, 659-659.	0.6	5
14	Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. Blood, 2018, 131, 759-770.	0.6	54
15	Single-cell heterogeneity in Sézary syndrome. Blood Advances, 2018, 2, 2115-2126.	2.5	78
16	SATB1 in Malignant T Cells. Journal of Investigative Dermatology, 2018, 138, 1805-1815.	0.3	38
17	A novel BLK-induced tumor model. Tumor Biology, 2017, 39, 101042831771419.	0.8	19
18	Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells. Scientific Reports, 2017, 7, 14516.	1.6	77

#	Article	IF	CITATIONS
19	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016, 127, 1287-1296.	0.6	86
20	The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2016, 136, 866-869.	0.3	4
21	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. Oncotarget, 2016, 7, 45730-45744.	0.8	45
22	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget, 2015, 6, 20555-20569.	0.8	78
23	IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle, 2014, 13, 1306-1312.	1.3	27
24	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood, 2014, 124, 761-770.	0.6	59
25	STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Research, 2014, 34, 5277-86.	0.5	15
26	Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell Lymphoma. Toxins, 2013, 5, 1402-1421.	1.5	66
27	Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood, 2013, 122, 943-950.	0.6	78